Broach Lifecare Hospital Ltd

As of November 6, 2025, Broach Lifecare is fairly valued with a PE Ratio of 20.23 and an EV to EBITDA of 11.78, showing a significant valuation gap compared to peers like Apollo Hospitals, while it has underperformed the Sensex year-to-date with a decline of 16.67%.

As of October 8, 2025, Broach Lifecare is considered very attractive due to its undervaluation, highlighted by a low PE Ratio of 10.35 compared to peers like Apollo Hospitals and Max Healthcare, a PEG Ratio of 0.00 indicating growth potential, and a year-to-date stock performance lagging at -21.06% against the Sensex's 4.65% return.

As of September 22, 2025, Broach Lifecare is considered an attractive investment with a PE ratio of 11.84, undervalued compared to peers like Max Healthcare and Apollo Hospitals, despite a year-to-date return of -9.72%.

As of September 19, 2025, Broach Lifecare is considered very attractive and undervalued, with a PE ratio of 10.93 and an EV to EBITDA of 11.78, significantly lower than competitors like Apollo Hospitals and Max Healthcare, despite a one-year stock performance lag of -25.38% compared to the Sensex's -0.67%.

As of September 19, 2025, Broach Lifecare is considered very attractive due to its undervalued status with a PE ratio of 10.93 and strong financial metrics, despite a recent stock decline of 25.38%, indicating potential for recovery compared to its expensive peers like Apollo Hospitals and Max Healthcare.

As of September 19, 2025, Broach Lifecare is considered a very attractive investment due to its undervalued status, with a PE ratio of 10.93 and an EV to EBITDA of 11.78, significantly lower than peers like Apollo Hospitals and Max Healthcare, despite a recent stock performance lagging behind the Sensex.

As of September 18, 2025, Broach Lifecare is considered undervalued with a PE ratio of 12.75 and an attractive valuation grade, despite a 1-year stock decline of -27.36%, contrasting with the Sensex's slight gain.

As of August 28, 2025, Broach Lifecare is considered undervalued with an attractive valuation grade, featuring a PE Ratio of 15.42, an EV to EBITDA of 15.35, and a ROCE of 13.19%, making it a more appealing investment compared to peers like Max Healthcare and Apollo Hospitals, despite a recent annual return of -43.44% and a year-to-date return of 17.59%.

As of August 26, 2025, Broach Lifecare is fairly valued with a PE ratio of 15.42 and a ROCE of 13.19%, making it more reasonably priced compared to peers like Max Healthcare and Apollo Hospitals, despite a significant 46.27% decline in stock performance over the past year.

As of August 26, 2025, Broach Lifecare is fairly valued with a PE ratio of 15.42 and has outperformed the Sensex in the short term, but its stock has declined by 46.27% over the past year, contrasting with much higher PE ratios of its peers like Max Healthcare and Apollo Hospitals.

As of August 20, 2025, Broach Lifecare is considered undervalued with an attractive valuation grade, featuring a PE Ratio of 15.42, an EV to EBITDA of 15.35, and a ROCE of 13.19%, significantly outperforming peers like Max Healthcare and Apollo Hospitals, while also achieving a 1-week stock return of 18.14% compared to the Sensex's 1.64%.

As of August 11, 2025, Broach Lifecare's valuation has shifted from attractive to risky, with a PE ratio of 13.05 indicating it is overvalued compared to its peers like Max Healthcare and Apollo Hospitals, but it has outperformed the Sensex year-to-date with a return of 5.93%.

As of 24th July, Broach Lifecare Hospital Ltd has a market capitalization of 12.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 5.47 Cr and Total Assets of 5.72 Cr; however, recent financial data for Net Sales and Net Profit is unavailable.

As of July 16, 2025, Broach Lifecare is considered undervalued with a PE ratio of 13.35 and favorable financial metrics compared to peers like Max Healthcare and Apollo Hospitals, indicating a significant improvement in its valuation from risky to attractive.

As of June 17, 2025, Broach is considered an attractive investment due to its undervalued status, with a PE ratio of 11.62 and a low PEG ratio of 0.00, despite a recent stock price decline.

The top shareholder of Broach is Jaykumar Narendra Vyas, holding 63.75% of the shares, with no pledged promoter holdings. The highest public shareholder is Kaushik Bhupatrai Joshi at 5.27%, while individual investors collectively own 33.77%.

The top shareholder of Broach is Jaykumar Narendra Vyas, holding 63.75% of the shares, with no pledged promoter holdings. The highest public shareholder is Kaushik Bhupatrai Joshi at 5.27%, while individual investors collectively own 33.77%.

Broach Lifecare Hospital Ltd, a micro-cap company incorporated in 2023, operates in the hospital industry after acquiring Dr. Jaykumar Narendra Vyas's Heart Hospital and Dr. Vyas Hospital. It has a market cap of Rs 14 Cr, with key metrics including a P/E of 13.00 and a return on equity of 13.01%.

Broach's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institute, Rainbow Child, Dr. Agarwal's Health, and Jupiter Life Line. Key metrics show excellent management risk and growth at Max Healthcare and Apollo Hospitals, while Krishna Institute leads in 1-year return at 85.24%.